Go Pro
NYSE:PEN

Penumbra Q1 2026 Earnings Report

Penumbra logo
$317.86 +0.08 (+0.03%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$317.73 -0.13 (-0.04%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Penumbra EPS Results

Actual EPS
$0.82
Consensus EPS
$1.06
Beat/Miss
Missed by -$0.24
One Year Ago EPS
$0.83

Penumbra Revenue Results

Actual Revenue
$374.76 million
Expected Revenue
$370.47 million
Beat/Miss
Beat by +$4.29 million
YoY Revenue Growth
+15.60%

Penumbra Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 6, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Penumbra's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Penumbra Earnings Headlines

Incuvate Files Patent Infringement Lawsuit Against Penumbra
My ‘one day’ retirement secret
TradeSmith's AI research team, backed by a $17 million investment and led by a former NSA codebreaker, built a tool that narrows the market down to just five stocks a month. In backtesting, that five-stock approach outpaced the broader market and big tech names like Microsoft and Amazon. More than 300,000 people have already viewed the demonstration. No daily chart-watching required, just a monthly check-in on five selected stocks.tc pixel
Penumbra: Q2 Earnings Snapshot
See More Penumbra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Penumbra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Penumbra and other key companies, straight to your email.

About Penumbra

Penumbra (NYSE:PEN) (NYSE:PEN) is a medical device company that develops, manufactures and markets products designed to treat neurovascular, vascular and other medical conditions. Its technologies are used by physicians in minimally invasive procedures, including the removal of blood clots, treatment of aneurysms and management of vascular disorders.

The company’s product portfolio includes aspiration and mechanical thrombectomy systems for ischemic stroke and pulmonary embolism, embolization devices for aneurysms and other vascular conditions, and access and peripheral vascular products. Penumbra also offers equipment and accessories that support interventional procedures.

Founded in 2004 and headquartered in Alameda, California, Penumbra serves hospitals and healthcare providers in the United States and international markets. The company was founded by Adam Elsesser, who serves as its chairman, president and chief executive officer. Its products are distributed through direct sales organizations and other commercial channels worldwide.

View Penumbra Profile